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ABSTRACT
The fluorescence ubiquitination-based cell cycle indicator (FUCCI) is
a powerful tool for use in live cells but current FUCCI-based assays
have limited throughput in terms of image processing and
quantification. Here, we developed a lentiviral system that rapidly
introduced FUCCI transgenes into cells by using an all-in-one
expression cassette, FastFUCCI. The approach alleviated the need
for sequential transduction and characterisation, improving labelling
efficiency. We coupled the system to an automated imaging workflow
capable of handling large datasets. The integrated assay enabled
analyses of single-cell readouts at high spatiotemporal resolution.
With the assay, we captured in detail the cell cycle alterations induced
by antimitotic agents. We found that treated cells accumulated at G2
or M phase but eventually advanced through mitosis into the next
interphase, where the majority of cell death occurred, irrespective of
the preceding mitotic phenotype. Some cells appeared viable after
mitotic slippage, and a fraction of them subsequently re-entered
S phase. Accordingly, we found evidence that targeting the DNA
replication origin activity sensitised cells to paclitaxel. In summary, we
demonstrate the utility of the FastFUCCI assay for quantifying
spatiotemporal dynamics and identify its potential in preclinical drug
development.
KEY WORDS: Automated microscopy, DNA replication origin, Drug
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INTRODUCTION
The fluorescence ubiquitination-based cell cycle indicator (FUCCI)
system represents a quantum leap for real-time examination of cell
cycle progression (Sakaue-Sawano et al., 2008). This technology
relies on the choreography of two players of the DNA replication
control apparatus, the licensing factor CDT1 and its inhibitor
geminin (Zielke and Edgar, 2015). In eukaryotic cells, CDT1 level
peaks during G1 and plummets upon S entry. Conversely, the
geminin level is high during S and G2 but is low during late mitosis
and G1. The alternating expression of these two proteins arises
from the sequential activation of the E3 ubiquitin ligases SCFSkp2
(a Skp1–cullin-1–F-box complex that contains Skp2 as the F-box
protein), and the anaphase-promoting complex/cyclosome (APC/
C), which target the degradation of CDT1 and geminin,
respectively. By fusing fluorescent proteins to degrons derived
from CDT1 and geminin, the FUCCI system thus enables
continuous visualisation of live cells in either G1 or the S- and/or
G2-to-M phases (hereafter denoted as S/G2-M).
To date, various FUCCI-based laboratory models have been
employed together with live-cell imaging to elucidate the effects of
therapeutic modulation (Sakaue-Sawano et al., 2011; Yano et al.,
2013; Dan et al., 2012; Koh et al., 2015). However, despite the
detailed molecular insights one can gain from such imaging, the
approach remains uncommon owing to its technical complexity. In
particular, advances in automated imaging hardware have not been
matched by the ease and accessibility of multiparametric image-
based processing workflows. As a result, many live-cell assays are
not designed with good throughput capability and often depend on
manual handling of a limited number of datasets (Chirieleison et al.,
2011; Boutros et al., 2015; Singh et al., 2014).
Here, we developed a rapid selectable lentiviral-based system
called FastFUCCI that allowed simultaneous introduction of both
FUCCI transgenes, that is the CDT1- and geminin-tagged reporters,
into cells. The method alleviated the conventional requirement for
sequential cell line transduction and characterisation, thereby
improving labelling efficiency. We coupled the FastFUCCI
system to a cascade of image acquisition, processing and analysis
streamlined for the single-cell level. This was achieved by
developing a versatile live-cell assay implemented in a modular
design, where each handling step was independently scalable and
automated by open-source scripts. A key feature of this assay was its
ability to perform batch management of high-volume data; the
quantitative output of these data was image-based and therefore
amenable to downstream validation.
To demonstrate the utility of the FastFUCCI imaging assay, we
applied it to define the cellular and molecular events in cancer cells
following treatment with antimitotic agents. Antimitotic agents
such as taxanes are frequently used for cancer treatment. These
agents disrupt mitotic progression, resulting in structural
aberrations that in turn elicit mitotic arrest. Although the
mechanism of these events is well described, comparatively little
is known about how cells respond to such insults spatiotemporally
(Gascoigne and Taylor, 2009; Rieder and Maiato, 2004). To this
end, we first monitored the cell cycle dynamics at the single-cell
level in response to treatment with varying concentrations of
paclitaxel and nocodazole. We then correlated the cell cycle
distributions with the temporal dimension, as quantified by single-
cell tracking of the different cell cycle phases. Using the
FastFUCCI assay revealed actionable spatiotemporal effects
induced by antimitotic agents, leading to evidence that co-
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RESULTS
Stable generation of the FastFUCCI reporter system
Traditional generation of a FUCCI-expressing cell line entails
sequential expression of the two FUCCI reporters, CDT1 and
geminin. To simplify this procedure, we directed the simultaneous
expression of both reporters in equimolar amounts by cloning both
transgenes [monomeric Kusabira Orange 2 (mKO2)–hCDT1(30–
120) and monomeric Azami Green (mAG)–hGEM(1–110), where
m denotes mouse and h denotes human], separated by a T2A
sequence, downstream of a single EF1α promoter. This expression
cassette was subsequently cloned into the lentiviral backbone pBOB
to permit fast generation of a cell population that stably expressed
both FUCCI reporters (Fig. 1A; Fig. S1, Table S1).
We introduced the expression of both FUCCI reporters in human
pancreatic cancer MIA PaCa-2 cells through lentiviral transduction.
In stably transduced cells, fluorescence was observed in the nuclei,
and both red (mKO2) and green (mAG) signals alternated
predictably according to the phases of the cell cycle (Fig. 1B).
Flow cytometric analysis shows comparable cell cycle distributions
in both parental and FastFUCCI-expressing cells (Fig. 1C). The
red-, yellow- and green-emitting populations in the latter
corresponded to cells in G1, the G1/S transition and S/G2-M,
respectively.
Automated extraction of FastFUCCI time-lapse data
The increasing use of multiparametric microscopy assays has
demanded workflows that can manage practical issues related to
processing and analysis of large datasets (Singh et al., 2014). To
acquire and analyse time-lapse data in an unbiased and automated
fashion, we proceeded to develop the FastFUCCI imaging assay
(Fig. 2A; Fig. S2A,B). We streamlined the assay with automation at
each principal step to afford user-independent handling of a high
number of images. The output was time-lapse data with consistent
image resolution and contrast, allowing downstream analyses to be
performed in batch mode by commercial and open-source image
analysis platforms, as tested with the Columbus™ Image Data
Storage and Analysis and Fiji, respectively, in this work (Fig. 2A).
To demonstrate these functional features, we performed a 12-h
study on the FastFUCCI-expressing MIA PaCa-2 cells treated with
the previously characterised CDK1-selective inhibitor RO3306,
which was expected to arrest cells at the G2/M boundary (Vassilev
et al., 2006). CDK1 inhibition induced a dose-dependent increase in
the green population and a corresponding decrease in the red
population (Fig. 2B). Consistent with previous studies, this effect on
single-cell spatiotemporal dynamics was rapid, as the apparent
difference was noticeable as early as 1 h following treatment,
reflecting an accumulation of S/G2-M cells (Vassilev et al., 2006;
Marcus et al., 2015). Automated single-cell duration measurement
showed that the increase in the S/G2-M population was correlated
with the residence time in the green phase (representing this
population), the latter also exhibiting a dose-dependent trend
(Fig. 2C).
Real-time monitoring of cell cycle modulation by antimitotic
agents
We exploited the assay to define the single-cell spatiotemporal
dynamics induced by paclitaxel at high definition. Based on the IC50
of paclitaxel (4.7±0.3 nM; mean±s.e.m.) (Fig. 3A), we subjected
FastFUCCI-expressing MIA PaCa-2 cells to a low (3 nM) and a
high (30 nM) concentration of paclitaxel. Cell cycle progression
was monitored, with total number of cells being taken as a parameter
for proliferation (Fig. 3B–E). We found that, in the vehicle control,
the fractions of red and green cells each displayed a reciprocally
oscillating profile as total cell count increased over time, in line with
the predicted behaviour of cycling single cells (Fig. 3B,C). In 3 nM
paclitaxel, the alternating oscillation remained evident, with
minimal changes in the cell cycle distributions consistent with the
minimal inhibition of proliferation (Fig. 3B,D). In contrast, in
Fig. 1. Generation of the FastFUCCImodel. (A) Design of the pBOB-EF1-FastFUCCI-Puro construct. See Fig. S1 for full map of the construct, and Table S1 for all
single and two-cutter 6+ nucleotide restriction enzymes with respective positions and actual nucleotide numbers. (B) Cell-cycle-dependent changes in
fluorescence in a FastFUCCI-expressing MIA PaCa-2 cell. The arrowhead denotes the mother cell that was tracked; arrows denote daughter cells arising from the
tracked mother cell. The number denotes time in minutes. Scale bar: 25 µm. (C) Cell cycle profile of parental and FastFUCCI-expressing MIA PaCa-2 cells
harvested in exponential growth, measured by flow cytometry. The Dean-Jett-Foxmodel was used to quantify G1, S andG2 andM (G2/M) fractions of the parental
line, based onDNAcontent asmeasured byDAPI. The FUCCI indicators were used to quantify theG1, G1/S transition andS/G2-M fractions of the FastFUCCI line.
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30 nM paclitaxel, there was an initial accumulation of the green
fraction up to 6 h (Fig. 3E). From 6 to 24 h, the green fraction
decreased with a concomitant rise in the red fraction, implying that
the initial mitotic arrest was followed by either mitotic death or
mitotic slippage (the process by which cells proceed through mitosis
to interphase without chromosome segregation). Given that cell
proliferation did not appear to decline until after 24 h, this suggests
that therewas mitotic slippage, rather than extensive death in mitosis
(Fig. 3B). Similar observations were made in paclitaxel-treated
FastFUCCI-expressing Panc-1 cells, where accumulation of green
cells was followed by accumulation of red cells (Fig. S3A–C).
To correlate the spatiotemporal dynamics with cell cycle residence
time, we quantified the cell cycle durations of individual FastFUCCI-
expressing MIA PaCa-2 cells under the same conditions (Fig. 3F,G).
In control, the average S/G2-M duration was 8.9±0.2 h (mean±
s.e.m.), comparable with previous results (Koh et al., 2015). Cells
treated with 3 nM paclitaxel experienced similar S/G2-M duration
(9.7±0.3 h), whereas those treated with 30 nM paclitaxel had almost
double the duration (16.1±0.6 h) compared to control. The dose-
dependent delay in S/G2-M was correlated with G1 prolongation
(Fig. 3G). All these effects on cell cycle dynamics were similarly
observed with nocodazole, another mitotic inhibitor, indicating that
the findings were not specific to taxanes (Fig. S3D–H).
Spatiotemporal analysis of taxane-induced cell death
The temporal dichotomy of the red and green fractions induced by
the antimitotic agents prompted us to use the FastFUCCI system to
determine the basis of their cytotoxicity (Fig. 3E; Fig. S3C,F). First,
we performed manual cell fate analysis of 30 nM paclitaxel-treated
FastFUCCI-expressing MIA PaCa-2 cells (Fig. 4A). Of the 190
randomly selected cells tracked for 72 h, all of them attempted
mitosis, with 2% eliminated during mitosis. In the remaining 98%,
three distinct mitotic phenotypes were identified: abortive mitosis
(no daughter, 57%), bipolar mitosis (two daughters, 32%),
multipolar division (three or more daughters, 9%).
Next, we determined the ensuing fate of cells that had progressed
through mitosis into the second cell cycle (Fig. 4B). Independent of
the nature of the preceding mitotic phenotype, the majority of these
cells (73–75%) died in the red phase (i.e. G1). An important
observation was that some of these cells arrived at the red phase
without overt reflattening before death and appeared
morphologically similar to those that underwent mitotic death in
green phase (Fig. 4C). The remaining fraction either died in the next
green phase (10–15%) or appeared to remain alive (12–16%)
(Fig. 4B).
To substantiate these live-cell FastFUCCI analyses, we
performed quantitative immunofluorescence of MIA PaCa-2 cells
Fig. 2. Automated image processing and analysis. (A) Schematic for the FastFUCCI imaging assay with examples of still images obtained from the automated
platform. Scale bar: 40 µm. See Materials and Methods for full details. Briefly, image processing involved colour-channel separation, data resizing, illumination
adjustment and improvement of the signal-to-noise ratio. Image analysis involved threshold setting and data extraction, such as object scoring and event
quantification. Ticks denote that the step was automated; open circle denotes that the step required user input. *Other compatible open-source packages include
CellCognition, CellProfiler and CellProfiler Analyst, and EBImage. (B) Image-based cell cycle profiling. FastFUCCI-expressing MIA PaCa-2 cells were treated as
indicated and were imaged for 12 h. Fractions of red, green and yellow cells were quantified using the Columbus™ software. Data shown were from three fields of
view per time point, with a mean total of 313 cells per condition scored. (C) The S/G2-M duration of FastFUCCI-expressing MIA PaCa-2 cells treated as indicated,
analysed using the Fiji software. Duration is reported as mean±s.e.m., n=45 cells per condition, collected from imaging for 24 h after drug addition.
514
TOOLS AND TECHNIQUES Journal of Cell Science (2017) 130, 512-520 doi:10.1242/jcs.195164
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
to enumerate the proportion of cells that were dead or dying in
mitosis. We employed cleaved caspase 3 (c-caspase 3) and cyclin
B1 as markers of apoptosis and mitosis, respectively (Fig. 5A).
Irrespective of treatment duration (0–48 h), we found that less than
30% of c-caspase-3-positive cells were positive for cyclin B1
(Fig. 5B). Validation using another apoptotic (γH2AX) and mitotic
(pHH3) markers yielded the same conclusion – that mitosis was not
the main phase in which cell death occurred (Fig. 5C,D; Fig. S4A).
All these results were verified in Panc-1 cells (Fig. S4B–D).
Interaction between taxanes and DNA replication origin
inhibitors
Our findings suggest that post-mitotic entry into subsequent
interphase is important for maximal paclitaxel cytotoxicity. To
test this hypothesis, we performed a series of scheduled washout
experiments on MIA PaCa-2 cells (Fig. 6A). We found that there
was a duration-dependent decrease in proliferation index compared
to time-matched controls (Fig. 6B). When the incubation time for
30 nM paclitaxel was limited up to 12 h (i.e. before the red fraction
overtook the green fraction in Fig. 3E), the proliferation index
remained above unity, indicating that cells had proliferated. A 24-h
incubation largely prevented subsequent proliferation whereas a
48-h incubation had a killing effect, consistent with the total cell
count dynamics in Fig. 3B.
Whereas drug incubation of at least 24 h appeared necessary for
short-term growth suppression, from the fraction of cells that
remained viable even following a 3-day treatment (Fig. 4B), 26%
subsequently re-entered S phase (Fig. 6C). Based on the paradigm
that re-entry into active cell cycle could underlie chemoresistance,
we investigated whether inhibiting the DNA replication origin firing
following paclitaxel treatment could improve chemosensitisation.
We performed long-term cell proliferation studies, where we
pretreated MIA PaCa-2 cells with 30 nM paclitaxel for 24 h and
released viable cells into roscovitine, a pan-CDK inhibitor
commonly used to suppress origin activity. As expected, we
found that 24-h paclitaxel pretreatment impaired but did not
obliterate proliferation compared to DMSO control (Fig. 6D,E).
Additional treatment with roscovitine further reduced the
proliferative capacity compared to the Bliss-predicted additivity
value, suggesting an apparent synergistic interaction. Replacement
of roscovitine with PHA767491 to inhibit CDC7, another
replication origin regulator, reproduced this potential synergistic
relationship with paclitaxel pretreatment. Similar results were
obtained in Panc-1 cells (Fig. 6D,E).
DISCUSSION
Devising methods to visualise single-cell states is an area of active
development (Walling and Shepard, 2011). In particular, as interest
in multiparametric imaging assays grows, the need for efficient
workflows that encompass data acquisition, processing and analysis
has become more evident (Chirieleison et al., 2011; Singh et al.,
2014). Here, we developed a selectable lentiviral reagent that
enables rapid expression of the two FUCCI reporter transgenes in
cells. We applied this FastFUCCI system to a streamlined imaging
workflow that performs automated image processing and analysis.
Practically, the FastFUCCI imaging workflow is supported by
Fig. 3. Real-time quantification of cell cycle modulation in paclitaxel-treated cells. (A) Dose–response curve for paclitaxel in parental MIA PaCa-2 cells
treated for 72 h as measured by a sulforhodamine B assay. Cell growth at the time of treatment (time zero) was subtracted from all samples and growth inhibition
was calculated by expressing it as a ratio of the mean of DMSO control. IC50 is reported as the mean±s.e.m., n=4. (B) Real-time monitoring of single-cell count.
FastFUCCI-expressing MIA PaCa-2 cells were treated as indicated and cell number was quantified every 30 min. Data shown were from three fields of view
per time-point, and each value was normalised to the initial cell count. (C–E) Fractions of red, green and yellow cells in samples treated as in B. Data shown were
from three fields of view per time-point, with amean total of 17,816 cells per condition scored. (F) S/G2-M and (G) G1 duration of individual FastFUCCI-expressing
MIA PaCa-2 cells treated as indicated. Duration is reported as mean±s.e.m., n=number of cells, collected from imaging for 72 h after drug addition.
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open-source scripts and is modular in its construction, with the
output being digital images of accessible format (TIFF). Hence, it is
amenable to current commercial and open-source image analysis
programmes, as demonstrated here by its coupling with the
Columbus™ and Fiji software, respectively. Analytically, the
workflow enables quantification of large numbers of images,
Fig. 4. Single-cell fate analysis following paclitaxel treatment. (A) Examples of FastFUCCI-expressing MIA PaCa-2 cell fate following treatment with 30 nM
paclitaxel. The arrowhead denotes the mother cell that was tracked; arrows denote daughters cell arising from the tracked mother cell. The number denotes
time in minutes. A total of 190 cells from two independent experiments were analysed. Scale bar: 25 µm. (B) Fraction of cells treated with 30 nM paclitaxel
for 3 days that had died in the subsequent red or green phase, or had remained alive following abortive, bipolar or multipolar mitosis. A total of 285 cells from
two independent experiments were analysed. (C) Examples of cell undergoing death in the red phase (top panel) and mitotic death (bottom panel). The
arrowhead denotes cell that was tracked. The number denotes time in minute. Scale bar: 25 µm.
Fig. 5. Correlation of paclitaxel-induced cell death andmitosis. (A) Immunofluorescence of parental MIA PaCa-2 cells treated with vehicle (DMSO, top panel)
or 30 nM paclitaxel (PAC, bottom panel) for 24 h. Dashed circles indicate cells that stain for either c-caspase-3 or cyclin B1. The cell in the middle of the bottom
panel was apoptotic with a highly fragmented nucleus. Scale bar: 25 µm. (B) Quantification of parental MIA PaCa-2 cells treated with 30 nM paclitaxel over the
course of 48 h. Each dot represents a single cell; black dots denote negative cells, blue dots denote c-caspase-3-positive cells, green dots denote cyclin-B1-
positive cells, red dots denote c-caspase 3 and cyclin B1 double-positive cells. The number denotes the percentage of c-caspase-3-positive cells that were
positive for cyclin B1. A total of >2000 single cells per time point were scored. (C) Quantification of parental MIA PaCa-2 cells treated with vehicle or 30 nM
paclitaxel for 48 h. Each dot represents a single cell: black dots denote negative cells, blue dots denote γH2AX-positive cells, green dots denote phosphorylated
histone H3 (pHH3)-positive cells, red dots denote γH2AX and pHH3 double-positive cells. The number denotes the percentage of γH2AX-positive cells that were
positive for pHH3. A total of >2000 single cells per condition were scored. (D) Examples (circles) of paclitaxel-treated MIA PaCa-2 cells in C. Scale bar: 25 µm.
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objects or events, conferring the statistical power necessary to
detect subtle, transient or rapid real-time dynamics (Hamilton,
2009). Extraction of multidimensional data at such a scale would
be a resource for studies attempting to integrate the FUCCI
technology with mathematical modelling (Saitou and Imamura,
2016). Equally, addition of other imaging features, such as shape
recognition, to the workflow would further diversify its
experimental applications.
To test the utility of the FastFUCCI imaging assay, we applied it
to dissect the spatiotemporal effects induced by antimitotic agents.
Earlier studies had attempted to establish a link between paclitaxel-
induced cell death and mitotic exit, but it remained unclear if mitotic
exit represented a major pro-death event (Bekier et al., 2009; Tao
et al., 2005; Gascoigne and Taylor, 2008; Shi et al., 2008; Huang
et al., 2009; Orth et al., 2008). Although the ambiguity might have
stemmed from interline variation, the understanding so far has been
drawn from cell-population-based experiments, phase-contrast
images or low-content microscopy, precluding the precise
discrimination between cells that die in mitosis and cells that die
following a mitotic attempt. More recently, several qualitative
studies using FUCCI-expressing cells have reported the emergence
of CDT1 expression following prolonged mitosis (Honda-Uezono
et al., 2012; Kaida et al., 2011; Marcus et al., 2015). Through in-
depth single-cell analyses, we found this phenomenon to be far
more common than previously implied. Importantly, we forged a
quantitative association between post-mitotic entry and cell death,
the latter being independent of the mitotic phenotype. Our results
are supported by previous studies that investigated the role of post-
mitotic entry in finalising apoptosis (Tao et al., 2005; Orth et al.,
2012). Further mechanistic studies are warranted to elucidate how
mitotic arrest and subsequent interphase entry differentially engage
the resolution of death.
Three therapeutic considerations arise from this work. First,
conventional regimens are often based on the principle of maximum
Fig. 6. Interaction between paclitaxel andDNA replication origin inhibitors. (A) Schematic for scheduled washout experiments. 30 nM paclitaxel waswashed
out after a specified duration, and parental MIA PaCa-2 cells were left to grow in fresh medium for 48 h. (B) Proliferation assays for the washout experiments
illustrated in A. Sulforhodamine B staining was used to determine proliferation indices, which were calculated from the ratio of cell number after the 48-h fresh
medium incubation to cell number at the time of treatment (time zero). (C) Quantification of the viable fraction of FastFUCCI-expressing MIA PaCa-2 cells in
Fig. 4B. The top panel shows an example of a cell undergoing abortivemitosis (arrowhead) and subsequently entering the green phase (arrow). The bottom panel
shows an example of a mother cell undergoing bipolar mitosis (arrowhead), with one daughter that eventually died (black arrow) and one daughter that appeared
alive in the red phase (white arrow). The number denotes time in minute. Scale bar: 25 µm. (D,E) Long-term cell proliferation studies. Parental MIA PaCa-2 or
Panc-1 cells were treated with 30 nM paclitaxel (PAC) for 24 h. Viable cells were then released into DMSO, 8 µM roscovitine or 2 µM PHA767491 and were
left to grow for 2 weeks. Crystal Violet absorbance was normalised to that of vehicle control. Data are represented as mean±s.e.m., n=3. A two-tailed t-test was
used to calculate the indicated P-value between the combination results and corresponding Bliss additivity prediction. See Materials and Methods for additivity
prediction calculation.
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tolerable doses (Marshall, 2012). We have shown that, even at a
cytotoxic concentration that elicits growth inhibition, cancer cells
do regain some extent of proliferative capacity when drug residence
falls below a critical threshold, that is when cells have not yet
progressed beyond mitosis and become committed to apoptosis.
This suggests that paclitaxel sensitivity depends not only on the
strength of the mitotic checkpoint but also on the extent of
checkpoint adaptation (Weaver and Cleveland, 2005). An
understanding of how these mechanisms enact in vivo in relation
to drug pharmacokinetics would inform future development of the
recently proposed adaptive strategy for paclitaxel (Enriquez-Navas
et al., 2016).
Second, our in vitro data using pancreatic cancer cell lines
recapitulate the phenomenon seen in a fibrosarcoma xenograft
model, whereby cancer cells accumulate in G1 following paclitaxel-
induced mitotic arrest (Chittajallu et al., 2015). Our high-definition
spatiotemporal analyses indicate that a large fraction of these cells
are the direct consequence of treatment, having progressed through
aberrant mitosis into G1 (Vakifahmetoglu et al., 2008; Shi et al.,
2008). Some of these cells appear viable, and most of them stay in
G1, presumably in an arrested or senescent mode. However, a few of
the survivors subsequently re-enter S phase. It is conceivable that
acquired resistance might arise from these cells that have been
therapeutically challenged but do not succumb (Ogden et al., 2015).
Third, a second agent that targets the surviving post-mitotic
population might confer further chemosensitisation. We
demonstrated this possibility with the synergistic interaction
between paclitaxel and roscovitine as well as PHA767491, two
compounds known to affect DNA replication origins. Other small-
molecule inhibitors with overlapping mechanisms, namely CINK4,
flavopiridol, PD-0332991 and purvalanol, have previously been
shown to enhance taxane cytotoxicity or reverse taxane resistance
(Zhang et al., 2013; Ingemarsdotter et al., 2015; Bible and
Kaufmann, 1997; O’Connor et al., 2002). As such a co-targeting
strategy is schedule dependent in most cases, the challengewould be
to identify optimum dosing regimens that could yield maximal
efficacy and minimal toxicity (Jackson et al., 2007; Shah and
Schwartz, 2001). We anticipate the FastFUCCI imaging assay to be
a useful preclinical tool in these endeavours.
MATERIALS AND METHODS
Gene construction
A synthetic linker was designed and cloned into pBluescript (pBS) to enable
the cloning of the FUCCI reporters [mKO2–hCDT1(30–120) and mAG–
hGEM(1–110); GeneArt Gene Synthesis] on either side of and in framewith a
T2A sequence. This whole cassette was then dropped from pBS and cloned
into a third generation lentiviral plasmid (pBOB), as a BamHI and NotI
fragment. An EF1α promoter, to drive robust and constitutive transgene
expression, was then cloned into pBOB upstream of the FUCCI cassette as a
PacI fragment. Finally, a PGK-PURO cassette was cloned as an NheI
fragment to enable in vitro selection of transduced cells with puromycin. The
essential components of the construct are illustrated in Fig. 1A, full map is in
Fig. S1, and all single and two-cutter 6+ nucleotide restriction enzymes with
respective positions and actual nucleotide numbers are in Table S1.
Cell lines
Generation of FastFUCCI-expressing cells was performed using VSV-G
pseudotyped lentiviral particles as previously described (Rodriguez et al.,
2014). Briefly, HEK 293T cells were transfected with pBOB-EF1-
FastFUCCI-Puro and packaging plasmids. Supernatant from the culture
medium containing virus was then collected and used to transduce human
pancreatic cancer MIA PaCa-2 and Panc-1 cells (European Collection of
Cell Cultures). Following puromycin selection, polyclonal cell populations
were expanded. The identity of both parental and transduced cell lines was
authenticated by STR genotyping. In all experiments, cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% foetal bovine
serum (GIBCO) and were used up to a maximum of 20 passages. All cell
lines were verified to be mycoplasma-free using the Mycoprobe
Mycoplasma Detection Kit (R&D Systems).
Chemicals
Nocodazole (Sigma), paclitaxel (Tocris or Cayman Chemical), PHA767491
(Tocris), RO3306 (Calbiochem) and roscovitine (Sigma) were dissolved in
dimethylsulphoxide (DMSO, Sigma), kept at −20°C and used within
3 months. The final working DMSO concentration was kept at 0.1%.
Flow cytometry
Cells were fixed with 4% paraformaldehyde and stained with DAPI. Red
and green fluorescence were captured by the BD LSR II flow cytometer
using a blue octagon detector array (488-nm laser) with 555 long-pass and
575/26 band-pass filters, and 505 long-pass and 530/30 band-pass filters,
respectively. DAPI was captured using a UV trigon detector array (355-nm
laser) with a 450/50 band-pass filter. 10,000 events were collected, and data
were processed using the FlowJo software (Tree Star).
Microscopy
Cells were seeded in glass bottom wells (ibidi GmbH) and were kept in a
humidified chamber under cell culture conditions. For each well, images
were taken from three or more fields of view, where there were no excessive
cell clumps so as to capture cells unaffected by potential cell–cell contact
inhibition and to facilitate downstream analyses. Images were acquired with
either a Nikon Eclipse TE2000-E microscope with a 20×0.45 NA long-
working distance dry objective equipped with a sCMOSAndor Neo camera,
or a Carl Zeiss Axio Observer Z1 with a 20×0.8 NA dry objective equipped
with an Axiocam 506 CCD camera. With the Nikon microscope, red and
green fluorescence were captured using a pE-300white CoolLED filtered by
Nikon FITC B-2E/C and TRITC G-2E/C filter cubes, respectively. With the
Zeiss microscope, they were captured using a pE-4000 CoolLED filtered by
Zeiss 38HE and 43HE filter cubes, respectively. To achieve optimal image
resolution without excessive illumination, a binning factor of 2 by 2 for the
sCMOS camera and 5 by 5 for the CCD camera was applied prior to
imaging. Throughout each experiment, the ambient conditions of the
imaging platform (e.g. external lighting) were maintained to minimise
variations in optical resolution and illumination.
Image processing of time-lapse data
Processing of acquired videos was achieved automatically with a script
written for Fiji (Schindelin et al., 2012). First, splitting of fluorescence
images as single-channel time-lapse videos was performed using the Bio-
Formats plug-in in order to convert files into the universal TIFF format. This
processing step would also reduce video size, especially if binning was not
applied during acquisition. Second, background subtraction and shading
correction were applied to individual fluorescence channels. Depending on
microscopy conditions (e.g. illumination source and objective shading
effect), either the ‘Subtract background’ feature in Fiji was applied directly,
or the Gaussian filter was used to evaluate and subtract the background.
Optionally, the ‘Bleach correction’ plug-in could be used to further reduce
auto-fluorescence. Together, these steps minimised intensity variation due
to wide-field illumination and improved the signal-to-noise ratio, thus
facilitating downstream analyses. A summary of the image processing
pipeline is illustrated in Fig. S2A. Links to relevant scripts are provided
below.
Automated cell cycle profiling and analysis
To monitor real-time cell cycle distribution, time-lapse images were
processed as described above and were analysed in batch mode using the
Columbus™ software (PerkinElmer). Image formatting was performed
automatically with a Fiji script, which was designed to create an additional
red–green merged channel and include time splicing. The resulting TIFF
time-lapse images were then imported to the Columbus™ database using
PerkinElmer Insight extension. Nuclear segmentation was performed on the
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merged red–green channel, optionally de-noised with Gaussian filtering, to
detect all relevant nuclei. Sorting was performed to discard objects at the
edges of field of view, as well as abnormally small and large objects by
minimum and maximum size filter, respectively. Classification of the red-,
yellow- and green-emitting populations was undertaken according to the
mean and maximum intensities of the fluorescence within the nuclear area.
Thresholds were defined based on the fluorescence charts generated by the
Columbus™ interface. Fig. S2B depicts the procedure taken to analyse the
data using the Columbus™ software. Scripts for image processing and
analysis in this section are available at https://github.com/pmascalchi/
FastFUCCI-cellcycle.
Automated single-cell tracking and analysis
For single-cell tracking, images were processed as described above and
were analysed in batch mode using the TrackMate plug-in available in the
Fiji package (Tinevez et al., 2016). This plug-in operated on a user-
specified framework that enabled automation of spot segmentation and
frame-to-frame spot-tracking. The Laplacian of Gaussian filter was
applied to detect spots, and the Linear Assignment Problem tracker was
used to track the movement of detected spots. Elimination of false
positives (i.e. tracks with short durations) was performed in the final step
of the automated protocol. The output included the xy coordinates and the
track durations of detected spots, as well as videos with tracking paths for
quality control. Batch analysis of videos was achieved using the AutoClick
Robot software (http://autoclick-robot.en.softonic.com), which allowed
automatic mouse clicks and keyboard inputs, complemented with a
customised Fiji script to manage sequential video opening, exported data
handling and file formatting. Scripts for image processing and analysis in
this section are available at https://github.com/pmascalchi/FastFUCCI-
tracking.
Quantitative fluorescence-based microscopy
Cells were fixed on glass bottom wells (ibidi GmbH) with 4%
paraformaldehyde, immunostained and processed as previously described
(Koh et al., 2015). Briefly, images were captured using the iCys laser
scanning cytometer (CompuCyte). A digital image was generated for each
photomultiplier on a pixel-to-pixel basis. Objects were scored based on
preset signal thresholds. The output was processed by the iCys software.
Antibodies
Primary antibodies against c-caspase 3 (#9664, 1:400), cyclin B1 (#4135,
1:1000) and pHH3 (#3377, 1:1600) were from Cell Signaling Technology.
γH2AX (#05-636, 1:2500) was from Millipore. Secondary antibodies
conjugated to Alexa Fluor 488 (#4408, #4412) and Alexa Fluor 647 (#4410,
#4414) were from Cell Signaling Technology and were used at 1:1000.
Cytotoxicity and long-term cell proliferation assays
For sulforhodamine B cytotoxicity assays, cells were fixed with
trichloroacetic acid following treatment and were stained with
sulforhodamine B dye. Fluorescent readout was obtained using the
Infinite 200 PRO microplate reader (Tecan) at excitation and emission
wavelengths of 488 nm and 585 nm, respectively. For long-term cell
proliferation assays, cells were first subjected to DMSO or paclitaxel
treatment for 24 h. Cell viability was then determined using Trypan Blue
exclusion, and equal numbers of viable cells were reseeded in fresh medium
containing DMSO, roscovitine or PHA767491. After 2 weeks, cells were
fixed and stained with 0.2% Crystal Violet (Sigma). Crystal Violet was
solubilised using 10% acetic acid and the absorbance was measured at
590 nm using the PHERAStar plate reader (BMG LABTECH). The Bliss
additivity prediction was derived fromRAB Bliss (a,b)=EA(a)•EB(b), where R
denotes the reference effect, E denotes the observed effect, A and B denote
the agents of interest, a and b denote their respective concentration.
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